m+Medelevator.RU
← Поиск публикаций
CJC open · 2026

Outcomes of No-Touch Vs Conventionally Harvested Saphenous Veins for Coronary Artery Bypass Surgery: Individual Patient Data Meta-Analysis Protocol.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Gregg Alexander C, Tian Meice, Gaudino Mario, Angelini Gianni, Fremes Stephen, Jeppsson Anders, Modrau Ivy Susanne, Redfors Bjorn, Sandner Sigrid, Sartipy Ulrik, Thelin Stefan, Hu Shengshou, James Stefan

Аннотация

The effect of no-touch (NT) vs conventional (CON) saphenous vein graft (SVG) harvesting on SVG patency and clinical outcomes in coronary artery bypass remains unclear. Although prior trial-level meta-analyses have generally reported improved patency with NT SVG, outcomes show variability across studies, and evidence from 2 recent, larger multicentre randomized clinical trials is discordant. This individual patient data meta-analysis (IPDMA) will evaluate the impact of harvesting techniques on graft patency and clinical outcomes. A systematic literature search was conducted for randomized clinical trials comparing NT SVG and CON SVG. Studies were eligible if they included at least 1 year of follow-up evaluation with graft imaging. The primary efficacy outcome will be graft failure, defined as graft-level study SVG occlusion. The secondary outcomes will include leg wound complications, patient-level graft failure, graft malfunction (composite of graft occlusion or stenosis), and major adverse cardiac events (MACE) defined as the composite of all-cause death, myocardial infarction, or any repeat revascularization. A 2-stage IPDMA will be performed. In the first stage, mixed-effects logistic regression models will be fitted separately within each trial. In the second stage, trial-level estimates will be pooled using random-effects models to generate overall effects. Prespecified subgroup analyses will be conducted via a 2-stage framework to evaluate potential effect modification by key patient-level characteristics. This IPDMA will enable more robust evaluation of the effect of harvesting techniques on SVG patency and clinical outcomes, leveraging patient-level datasets for in-depth analyses, particularly among patient subgroups with distinct risk profiles.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты